Full text

Turn on search term navigation

© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

[...]the efficacy of the currently available agents varies from patient to patient, and a still considerably high number of subjects fail to respond. Since the suboptimal response and the lack of prognostic predictors constitute significant health and economic burden, further research directed towards identifying novel therapeutic targets for the treatment of psoriasis/PsA and RA is needed. Interestingly, the specific targeting of IL-36 by blocking its receptor (IL-36R) has already shown compelling anti-inflammatory effects in skin psoriasis; however, exploiting the properties of the antagonists IL-37 and IL-38 may represent an even more powerful weapon to inhibit IL-1-, Toll-Like Receptor (TLR)-, and IL-36-driven inflammation. Neutrophil extracellular traps (NETs), in addition to their antimicrobial role, can also serve as a platform for the activation of IL-1α and IL-36 cytokines through NETs-associated cathepsin-G and NE [15]. [...]neutrophils appear to be the principal cells responsible for IL-36 cytokines maturation via their secretory mechanisms. [...]they play an essential regulatory role on the IL-36-axis activity in skin- and joint-related inflammatory diseases [16].

Details

Title
IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential
Author
Marie-Astrid Boutet; Nerviani, Alessandra; Pitzalis, Costantino
Publication year
2019
Publication date
2019
Publisher
MDPI AG
ISSN
16616596
e-ISSN
14220067
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2332196867
Copyright
© 2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.